EN DE
STOCK COMPARISON

Swedish Orphan Biovitrum AB (publ) vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Swedish Orphan Biovitrum AB (publ) (SOBI) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Swedish Orphan Biovitrum AB (publ) trades at SEK 446 versus a fair value of SEK 62.98 (-86%), while Jiangsu Hengrui Medicine Co trades at ¥52.11 versus ¥25.94 (-50%).
Swedish Orphan Biovitrum AB (publ)
SOBI.ST · SEK · Health Care
-86%
upside to fair value
overvalued
PriceSEK 446
Fair ValueSEK 62.98
Quality66/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-50%
upside to fair value
overvalued
Price¥52.11
Fair Value¥25.94
Quality59/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Swedish Orphan Biovitrum AB (publ)Jiangsu Hengrui Medicine Co
Valuation
178.5×P/E (TTM)43.6×
5.65×P/S (TTM)10.84×
4.34×P/B5.76×
14.4×EV/EBITDA33.0×
0.34×PEG0.93×
Dividend yield0.4%
Dividend per share¥0.20
Profitability
3%Net margin25%
27%Operating margin32%
2%Return on equity15%
7%Return on assets9%
Growth
11%Revenue growth (YoY)13%
14.5%Avg. growth/yr (3Y)13.9%
13.1%Avg. growth/yr (5Y)2.5%
Balance & size
0.14×Debt / equity
$17BMarket cap$52B
healthyGrowth qualityhealthy

Even match: 6 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Swedish Orphan Biovitrum AB (publ)of which business quality 60 · market factors 83 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 42
ProfitabilityMargins and returns on capital today
23
63
Quality GrowthAre margins and returns improving?
44
41
CashflowEarnings quality: real cash, not paper profit
100
82
Fin. StrengthBalance sheet, leverage, solvency risk
64
100
InvestmentDisciplined investing over empire-building
65
27
Low VolatilityCalm price path (market factor)
86
78
MomentumPrice trend over the last 3–12 months (market factor)
76
30
52W MomentumDistance to the 52-week high (market factor)
91
23
Net IssuanceBuybacks instead of dilution
60
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Swedish Orphan Biovitrum AB (publ)

DCF ModelsSEK 541
Earnings-BasedSEK 44.66
MultiplesSEK 110
Asset-BasedSEK 73.07
Growth DCFSEK 542
Economic ProfitSEK 211
Growth EarningsSEK 35.81

18 of 24 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.11
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥22.37
Asset-Based¥6.44
Growth DCF¥38.47
Economic Profit¥18.21
Growth Earnings¥29.68

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Swedish Orphan Biovitrum AB (publ)
Bear SEK 26.13Fair Value SEK 62.98Bull SEK 88.22
SEK 446 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥52.11 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Swedish Orphan Biovitrum AB (publ) · Health Care

Quality score66 · Top 25%
Fair value upside-86% · bottom 25%

Jiangsu Hengrui Medicine Co · Health Care

Quality score59 · Top 25%
Fair value upside-50% · below median

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Swedish Orphan Biovitrum AB (publ) trades at SEK 446 versus a fair value of SEK 62.98 (-86%), while Jiangsu Hengrui Medicine Co trades at ¥52.11 versus ¥25.94 (-50%).

Swedish Orphan Biovitrum AB (publ) has the higher quality score (66/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.